

Voyageur Pharmaceuticals Strengthens Leadership Team with Strategic Appointment of Dr. Ibrahim Hashmi as VP of Business Development

written by Raj Shah | September 24, 2024

September 24, 2024 ([Source](#)) – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Company”) is pleased to announce the appointment of Dr. Ibrahim Hashmi as Vice President of Business Development, as key strategic move that signals the company’s commitment to accelerating its commercial initiatives and expanding its global footprint in the medical imaging industry.

Dr. Hashmi brings a wealth of expertise to Voyageur, with more than 25 years of experience in leading high-performance business and medical teams across global markets, including Asia Pacific, the Middle East, Africa, and Central Asia. His extensive leadership experience with multinational corporations, including his roles at GE Healthcare and Amersham health, positions him as a critical asset in Voyageur’s mission to drive strategic market expansion and secure a competitive edge in the rapidly evolving medical imaging and healthcare landscape.

Throughout his career, Dr. Hashmi has been instrumental in executing large scale business strategies, fostering strategic partnerships and driving operational excellence. His roles as Commercial Head at GE Healthcare for the Middle East, Africa, Central Asia, and Turkey, along with his most recent position as Head of Marketing and Commercial GM for Asia Pacific and ASEAN

at GE Healthcare, demonstrate his ability to spearhead business development initiatives in complex multinational environments.

“Dr. Hashmi’s appointment marks a pivotal moment for Voyageur as we embark on our journey to establish a stronger presence in the global medical imaging industry.” said Brent Willis, CEO of Voyageur Pharmaceuticals. “His proven ability to develop successful commercial strategies and drive growth will be instrumental as we work to expand our product portfolio, cultivate strategic partnerships, and establish a stronger foothold in international markets.”

Dr. Hashmi’s leadership will be key to advancing Voyageur’s strategic priorities, particularly as the company focuses on scaling its operations and introducing its high-quality, sustainably sourced medical imaging contrast media products to new markets. His expertise in integrating clinical insights with business development strategies will help Voyageur navigate the complexities of the medical imaging market while driving significant commercial impact.

“I am honored to join Voyageur at such an exciting time in its growth trajectory,” said Dr. Hashmi. “The company’s vision to deliver cost-efficient, sustainable medical imaging solutions resonates deeply with my own commitment to advancing healthcare. I look forward to collaborating with the team to accelerate our growth and become a preferred partner in the imaging contrast media market.”

The appointment of Dr. Hashmi is a clear testament to Voyageur’s long-term vision of becoming a leader in the medical imaging sector. His extensive experience, combined with his deep understanding of global healthcare dynamics, positions Voyageur to capitalize on emerging opportunities and strengthen its competitive positioning in the years to come.

This strategic hire further underscores Voyageur's dedication to building a world-class executive team capable of executing its ambitious growth strategy and driving sustained commercial success.

About Voyageur

Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own barium, iodine, and endo fullerenes.

Voyageur's business plan is expected to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.

Voyageur is committed to sustainability and environmental stewardship. Voyageur envisions a future where reducing carbon emissions is the norm, and to achieve this, it intends to build state-of-the-art carbon-capture infrastructure utilising the Rain Cage *EDENTM* system. By investing in carbon capture energy sources and sustainable manufacturing practices, Voyageur aims to generate revenue from carbon captured "advanced carbon production" to accelerate growth. Voyageur's unwavering commitment to the environment sets it apart as a pioneer in the industry.

At the core of its operations, Voyageur owns a 100% interest in

the Frances Creek barium sulphate (barite) project. Currently, the world's pharmaceutical barium sulphate is almost entirely synthetically produced resulting in a less effective imaging quality product. Voyageur's Frances Creek resource boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with higher quality imaging products.

Voyageur's ambitious vision is to become the first vertically integrated company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, Voyageur ensures quality and cost efficiency. With its approach, it embodies the motto of **"From the Earth to the Bottle,"** highlighting Voyageur's commitment to responsible sourcing and manufacturing practices.

For Further Information:

Brent Willis, CEO,	Albert Deslauriers, CFO,
Brent@vpharma.ca, 403-923-5944	Albert@vpharma.ca
info@vpharma.ca	https://voyageurpharmaceuticals.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding "Forward-Looking" Information

This news release contains statements that constitute "forward-looking statements" which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking

statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, “likely”, “probably”, “often”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to: receipt of regulatory approval of Dr. Ibrahim Hashmi’s appointment as Vice President of Business Development, and his potential contributions to the Company. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.